News & Updates
Filter by Specialty:
Long COVID symptoms may persist 3 years post-infection
One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.
Long COVID symptoms may persist 3 years post-infection
01 Oct 2025
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
Results from the phase III HARMONi trial presented at WCLC 2025 show that adding ivonescimab to chemotherapy prolongs progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
30 Sep 2025
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
29 Sep 2025
Multimodal AI system improves accuracy in identifying interstitial pneumonia
The multimodal artificial intelligence (AI) algorithm that combines computed tomography (CT) and histopathological images improves diagnostic accuracy, consistency, and confidence of pathologists in identifying usual interstitial pneumonia (UIP) in patients with resected lung specimens, reports a study.
